Today's Research Report Coverage on Biotech Stocks -- Rexahn Pharma, Protalix BioTherapeutics, Navidea Biopharma, and Biostage

NEW YORK, July 19, 2017 /PRNewswire/ --

If you want a Stock Review on RNN, PLX, NAVB, or BSTG then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. Pre-market, DailyStockTracker.com scans Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), Protalix BioTherapeutics Inc. (NYSE MKT: PLX), Navidea Biopharmaceuticals Inc (NYSE MKT: NAVB), and Biostage Inc. (NASDAQ: BSTG). According to an article on InvestorPlace, Biotech and Pharma stocks have bounced back this year. The SPDR S&P Biotech ETF has gained 34% in 2017, and the iShares NASDAQ Biotechnology Index ETF has gained 19%. Learn more about these stocks by signing up for their free reports on DailyStockTracker.com at: http://dailystocktracker.com/register/

Rexahn Pharma 

On Tuesday, shares in Rockville, Maryland headquartered Rexahn Pharmaceuticals Inc. recorded a trading volume of 111,993 shares. The stock ended the session 1.69% lower at $2.32. The Company's shares have surged 63.50% on an YTD basis. The stock is trading 16.89% below its 200-day moving average. Moreover, shares of Rexahn Pharma, which discovers, develops, and commercializes treatments for cancer, have a Relative Strength Index (RSI) of 27.88.

On July 10^th, 2017, Rexahn Pharma announced that the US Patent and Trademark Office has issued a Notice of Allowance for US Patent Application No. 15/178,390, "Fluorocyclopentenylcytosine Methods of Use". The patent application covers indications, dosage regimens, and pharmacokinetic profile for RX-3117. The patent is expected to be issued within a few months from the notice of allowance, and is expected to provide protection to 2036. The free research report on RNN is available at: http://dailystocktracker.com/registration/?symbol=RNN

Protalix BioTherapeutics 

Karmiel, Israel-based Protalix BioTherapeutics Inc.'s stock closed the day 1.26% lower at $0.79 with a total trading volume of 231,701 shares. The Company's shares have advanced 77.53% since the start of this year. The stock is trading 3.88% above its 200-day moving average. Additionally, shares of Protalix BioTherapeutics, which focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally, have an RSI of 46.79. The complimentary report on PLX can be downloaded at: http://dailystocktracker.com/registration/?symbol=PLX

Navidea Biopharma 

Shares in Dublin, Ohio headquartered Navidea Biopharmaceuticals Inc recorded a trading volume of 161,898 shares. The stock ended yesterday's trading session 1.47% lower at $0.48. The Company's shares have advanced 1.50% in the previous three months. The stock is trading below its 50-day moving average by 3.68%. Furthermore, shares of Navidea Biopharma, which focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, have an RSI of 43.50.

On June 20^th, 2017, Navidea Biopharma announced that it has entered into an exclusive license and distribution agreement with Sayre Therapeutics for the development and commercialization of Tc 99m tilmanocept in India. Under the terms of the agreement, the former received an upfront payment, and is eligible to receive upcoming milestone payments and double-digit royalties associated with the sale of Tc 99m tilmanocept. Visit us today and download our complete research report on NAVB for free at: http://dailystocktracker.com/registration/?symbol=NAVB

Biostage 

Holliston, Massachusetts headquartered Biostage Inc.'s stock finished Tuesday's session 0.93% lower at $0.53. A total volume of 1.68 million shares was traded, which was above their three months average volume of 741,520 shares. The Company's shares have surged 64.50% in the last one month and 78.96% over the previous three months. The stock is trading above its 50-day moving average by 54.35%. Additionally, shares of Biostage, which engages in developing bioengineered organ implants based on its Cellframe technology, have an RSI of 70.37.

On July 10^th, 2017, Biostage announced that the NASDAQ Hearings Panel (the "Panel") has granted the Company's request for continued listing on NASDAQ. The continued listing is subject to a number of conditions, with the Panel's decision ultimately requiring that the Company evidence full compliance with all requirements for continued listing on The NASDAQ Capital Market, including the $1.00 bid price and $2.5 million stockholders' equity requirements, by no later than November 13^th, 2017. Get free access to your technical report on BSTG at: http://dailystocktracker.com/registration/?symbol=BSTG

--

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@dailystocktracker.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: contact@dailystocktracker.com
Phone number:  (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA